Biogen’s business has been in decline thanks to fierce multiple sclerosis competition and a botched Alzheimer’s drug launch. To make matters worse, the U.S. Department of Justice is looking into the company’s foreign operations.Biogen has received a subpoena from the DOJ seeking information about its “business operations in several foreign countries,” the company disclosed in […]
